Back to News >

We are delighted to welcome Quotient Sciences, a global drug development and manufacturing accelerator, as a partner of the Medicines Manufacturing Innovation Centre. Quotient brings its vast experience in digital pharmaceutical manufacturing and end-to-end drug development solutions for global pharmaceutical and biotechnology companies to help drive efficiency within the medicines supply chain.

The Medicines Manufacturing Innovation Centre is a collaboration between CPI, the University of Strathclyde and founding industry partners GSK and AstraZeneca, along with funders Scottish Enterprise and UK Research and Innovation. The collaboration develops digitally disruptive technologies through a series of flagship ​‘Grand Challenge’ projects to increase efficiencies in the pharmaceutical industry, leading to improved outcomes for patients.

The company will support the Medicines Manufacturing Innovation Centre’s three Grand Challenges and will contribute to reducing material waste, cost, and the environmental footprint of medicines manufacturing.

Quotient will be involved in projects including:

• Grand Challenge 1 — Developing an innovative continuous direct compression platform to allow much greater process control than traditional batch manufacturing.
• Grand Challenge 2 — Delivering an automated clinical trial packing line that can be linked to a qualified person dashboard for real-time batch release.
• Grand Challenge 3 – Developing a scalable, sustainable and more cost-effective medicines manufacturing process for oligonucleotides: a promising class of medicine with the potential to treat a range of rare and chronic diseases.

Quotient’s expertise will support the development of advanced process controls, which improve the end-product quality, process reliability and overall productivity. This technology will help to drive the adoption of alternative analytical methods in the pharmaceutical industry where process analytical tools and inline sensors are not suitable due to chemical or environmental conditions.

Quotient’s work will enhance the productivity of medicines manufacturing processes, reduce costs and risk for end-users across the pharmaceutical industry.

Dave Tudor, Managing Director at the Medicines Manufacturing Innovation Centre, said: ​

“We are thrilled to be working with Quotient Sciences and to be able to draw on their expertise in digital technology for pharmaceutical manufacturing. The technology developed at the Medicines Manufacturing Innovation Centre will be a valuable asset, helping pharmaceutical companies to develop formulations faster and at a reduced cost.”

Gareth Jenkins, Vice President of Science and Technology at Quotient Sciences, added:

​“We are excited to become a part of the Medicines Manufacturing Innovation Centre and the opportunity this will provide to contribute our science and agility to the delivery of the Grand Challenges. Accelerating drug development and manufacturing is central to everything we do at Quotient and innovation, through digital technologies, is key to transforming modern medicines manufacturing — to get new medicines to patients faster.”

Find out more here.